Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the …

DR Spigel, MS Rubin, VG Gian, DL Shipley… - Lung Cancer, 2017 - Elsevier
Purpose To evaluate the efficacy of erlotinib, continued after tumor progression, plus
sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung …
被引用次数：11 相关文章

Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the …

DR Spigel, MS Rubin, VG Gian, DL Shipley… - Lung …, 2017 - lungcancerjournal.info
Purpose To evaluate the efficacy of erlotinib, continued after tumor progression, plus
sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung …

Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the …

DR Spigel, MS Rubin, VG Gian… - Lung cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Purpose To evaluate the efficacy of erlotinib, continued after tumor progression, plus
sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung …

Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the …

DR Spigel, MS Rubin, VG Gian, DL Shipley… - Lung Cancer …, 2017 - europepmc.org
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell
lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon …